EML4 and neoplasm: Various fusion partners have been described, including TPM3-NTRK1, LMNA-NTRK1, RBPMS-NTRK3, TPR-NTRK1, EML4-NTRK3, and SPECC1L-NTRK3 [14,16,17,18], with TPM3-NTRK1 being the most common and present in more than 60% of these tumours [18].